Evidence
Explore case studies and scientific evidence about STELFONTA® (tigilanol tiglate injection):
Case studies
Explore our interactive case studies and see how STELFONTA® has delivered results in tumors across different locations in different breeds of dogs.
Click the images to enlarge and see each case.
TAP A LOCATION
| Breed : | |
|---|---|
| Age : | |
| Tumor : | |
Case summary
| Dog weight : | kg |
|---|---|
| Tumor volume : | cm3 |
| Doses received : | |
| Complete response achieved | |
|---|---|
Case notes
Remember
- It is vital that pre- and post-treatment medications must be given to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation.
- Formation of wounds is an intended and likely response to treatment with STELFONTA along with the associated swelling, bruising and pain; these wounds are expected to heal.
Key Publications
Click on the title below for open access publications.
Understanding the Biology of the Fontainea picrosperma Tree
Tigilanol Tiglate Mode of Action in Mouse Models
Dose Characterization of Tigilanol Tiglate in Canine Mast Cell Tumors
U.S. Clinical Safety and Efficacy Trial
Wound Healing After Treatment with Tigilanol Tiglate
Recurrence-free Interval 12 Months After Treatment
Tigilanol Tiglate Margins vs. Surgical Margins
High Grade Mast Cell Tumors and Tigilanol Tiglate
Additional Publications and Conference Proceedings